Tone mix
Week by week 52 weeks
Share of Monte Rosa Therapeutics, Inc. Common Stock's 128 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Sep 7, 2026 · tone +99Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)+119
- Week of Mar 23, 2026 · tone +100Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Consensus Rating of "Moderate Buy" by Brokerages+100
- Week of Aug 24, 2026 · tone +50Monte Rosa Therapeutics' (GLUE) "Buy" Rating Reiterated at Guggenheim+80
- Week of Aug 10, 2026 · tone -100Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target Cut to $27.00 by Analysts at JPMorgan Chase & Co.-76
- Week of Feb 2, 2026 · tone -32Zacks Research Downgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to Hold-71
- Week of Jun 1, 2026 · tone +99Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy+71
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Monte Rosa Therapeutics, Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 2 | 0 |
| Last 30 sessions | 14 | +28 |
| Last 90 sessions | 35 | +5 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Thursday, October 22, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletMannKind (NASDAQ:MNKD) and Monte Rosa Therapeutics (NASDAQ:GLUE) Head-To-Head AnalysisNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| MannKind (NASDAQ:MNKD) and Monte Rosa Therapeutics (NASDAQ:GLUE) Head-To-Head Analysis | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 21, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletMonte Rosa Therapeutics (NASDAQ:GLUE) versus Krystal Biotech (NASDAQ:KRYS) Head to Head SurveyNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Monte Rosa Therapeutics (NASDAQ:GLUE) versus Krystal Biotech (NASDAQ:KRYS) Head to Head Survey | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 20, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletInvestors Buy Large Volume of Monte Rosa Therapeutics Call Options (NASDAQ:GLUE)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Investors Buy Large Volume of Monte Rosa Therapeutics Call Options (NASDAQ:GLUE) | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 19, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletComparing Monte Rosa Therapeutics (NASDAQ:GLUE) and Emergent Biosolutions (NYSE:EBS)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Comparing Monte Rosa Therapeutics (NASDAQ:GLUE) and Emergent Biosolutions (NYSE:EBS) | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 15, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.dailypolitical.com · 1 outletMonte Rosa Therapeutics (NASDAQ:GLUE) vs. MannKind (NASDAQ:MNKD) Critical SurveyNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Monte Rosa Therapeutics (NASDAQ:GLUE) vs. MannKind (NASDAQ:MNKD) Critical Survey | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Monte Rosa Therapeutics, Inc. Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.